References
- Cantley L C. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655–1657
- Vanhaesebrock B, Leevers S J, Ahmadi K, Timms J, Katso R, Driscoll P C, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001; 70: 535–602
- Samules Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554
- Lee J W, Soung Y H, Kim S Y, Lee H W, Park W S, Nam S W, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24: 1477–1480
- Müller C I, Miller C W, Hofmann W K, Gross M E, Walsh C S, Kawamata N, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leukemia Res 2007; 31: 27–32
- Abubaker J, Bavi P P, Al Harbi S, Siraj A K, Al-Dayel F, Uddin S, et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 2007; 21: 1–3
- Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, et al. Constitutively activated phosphstidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cδ. Blood 2002; 100: 3741–3748
- Michie A M, Nakagawa R. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia. Hematol Oncol 2006; 24: 134–138
- Longo P G, L Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007; 21: 110–120
- Carpten J D, Faber A L, Horn C, Donoho G P, Briggs S L, Robbins C M, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448: 439–444
- Mahmoud I S, Sughayer M A, Mohammad H A, Eshtayeh A A, Awidi A S, EL-Khateeb M S, et al. The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br J Cancer 2008; 99: 488–490